<DOC>
	<DOC>NCT01419457</DOC>
	<brief_summary>This study is designed to determine the pharmacokinetics of favipiravir in volunteers with hepatic impairment and in healthy control volunteers.</brief_summary>
	<brief_title>Pharmacokinetics of Favipiravir in Volunteers With Hepatic Impairment</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>Hepatically impaired groups: Agree to doctor approved birth control methods from Day 1 until 3 months following the final dose of study drug. Have mild hepatic impairment (ChildPugh Clinical Assessment Score Grade A, score 5 6) or moderate hepatic impairment (ChildPugh Clinical Assessment Score Grade B, score 79) or severe hepatic impairment (ChildPugh Clinical Assessment Score Grade C, score 1015); Control group Agree to doctor approved birth control methods from Day 1 until 3 months following the final dose of study drug. Healthy as determined by medical history, physical exam, vital signs, ECGs, and clinical laboratory tests. Hepatically impaired groups: Have used any drugs known to significantly affect hepatic metabolism within 28 days, or is unable or unwilling to forgo the use of such products throughout the study; Have any acute or unstable condition or disease, other than impaired hepatic function, as determined by medical history, physical exam, ECG and clinical laboratory tests; Known ongoing alcohol and/or drug abuse within 1 month Any evidence of progressive worsening liver function disease as indicated by laboratory values; Have had an acute flare of hepatitis A or B within 6 months; Have acute, fulminant alcoholic hepatitis, determined either clinically or by histology; Have a history of hepatoma or metastatic disease of the liver; Control group: Have used any drugs known to significantly affect hepatic metabolism within 28 days, or is unable or unwilling to forgo the use of such products throughout the study; Have a history or presence of clinically cardiovascular, dermatologic, endocrine, gastrointestinal, hematologic, hepatic, immunologic, neurologic, oncologic, psychiatric, pulmonary, or renal disease or any other condition.</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Healthy</keyword>
	<keyword>hepatic impairment</keyword>
	<keyword>T-705a</keyword>
	<keyword>Favipiravir</keyword>
</DOC>